BioSpace News Archive

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces the appointment of Quyen Dao-Haddock to its Board of Directors, effective immediately, increasing Board membership to eight.

Silicon Catalyst, the world’s only incubator focused exclusively on accelerating semiconductor solutions, is pleased to announce that EXOKĒRYX has been accepted into the Silicon Catalyst Incubator program.

Mirum Pharmaceuticals, Inc., a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, announced that it will participate in the following upcoming investor conferences: Evercore ISI HealthCONx Conference on Tuesday, November 29, 2022.

ArrePath today announced that it has appointed two new members to its Scientific Advisory Board (SAB): Connor Coley, PhD, Henri Slezynger (1957) Career Development Assistant Professor in Chemical Engineering at MIT, and Paul Hergenrother, PhD, Kenneth L. Rinehart Jr. Endowed Chair in Natural Products Chemistry, and Professor of Chemistry at the University of Illinois Urbana-Champaign.

Coloplast’s SpeediCath® Flex Set catheter developed for people living with bladder and urinary problems is now cleared in the U.S. and will be launched in November 2022.

- Data indicate continued clinical responses with an acceptable safety profile in heavily pre-treated patients with late-stage synovial sarcoma after a single dose of afami-cell

After statins, the next leading class of medications for managing cholesterol are PCSK9 inhibitors.

Avadel Pharmaceuticals plc, a biopharmaceutical company focused on transforming medicines to transform lives, announced that the United States District Court for the District of Delaware ordered Jazz Pharmaceuticals to delist U.S. Patent No. 8731963 from the U.S. Food and Drug Administration’s Orange Book.

Ultragenyx Pharmaceutical Inc. reported the grant of non-qualified stock options to purchase an aggregate of 5,380 shares of common stock of the company and 5,000 restricted stock units of the company’s common stock to one newly hired non-executive officer of the company.

Inhibrx, Inc., a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, announced it will be presenting at the following upcoming virtual investor conference.